Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma

Glioblastoma Clinical Trial

— GLINERA  

Official title:

Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06418113
• Other study ID #: 22/399
• Status: Recruiting
• Phase: Phase 1
• Start date: March 21, 2024
• Est. completion date: March 21, 2027

Study information

• Verified date: May 2024
• Source: Hospital San Carlos, Madrid
• Contact: Juan Antonio Barcia
• Phone: +34 913303506
• Email: jabarcia[@]ucm.es
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the safety and efficacy of neoadjuvant radiochemotherapy in the surgical resection of glioblastoma (GBM). The main questions it aims to answer are:

• What is the safety profile of neoadjuvant radiochemotherapy in terms of neurological deficit, radionecrosis, edema, headache, wound dehiscence, infection, and cerebrospinal fluid fistula?

• What is the efficacy of neoadjuvant radiochemotherapy in terms of progression-free survival, overall survival, cognitive function, and quality of life?

Participants will undergo the following tasks and treatments:

• Stereotactic biopsy and diagnosis confirmation.

• Conformal hypofractionated stereotactic radiotherapy with concurrent temozolomide.

• Supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring.

• Maintenance temozolomide administration for 6 months.

Researchers will compare the group receiving neoadjuvant radiochemotherapy to the control group following the standard Stupp protocol to assess safety and efficacy outcomes.

Description:

Objectives: To study the safety (primary) and efficacy (secondary) of neoadjuvant radiochemotherapy in the surgical resection of glioblastoma (GBM). Safety measures include: neurological deficit, radionecrosis (radiological and clinical), edema, headache, wound dehiscence, infection, and cerebrospinal fluid fistula. Efficacy measures include progression-free survival (PFS), overall survival (OS), cognitive function (MoCA Scale), and quality of life (EuroQol scales, EORTC QLQ-HN35, FACT-Br, and TWiST). Methods: Pilot safety and efficacy study in 6 patients compared to 6 controls. 2-year follow-up. A data safety monitoring committee will review the data one month after surgery for each of the first three patients to decide whether to stop or continue the study. Stereotactic biopsy will be performed, and if GBM is diagnosed, patients will undergo conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy and concurrent temozolomide (TMZ). 5 weeks later, patients will undergo supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring. 7 days after surgery, maintenance TMZ will be administered for 6 months. The control group will follow standard treatment (Stupp protocol). Data analysis will be performed using non-parametric tests. Samples from successive surgeries will be studied with histology, molecular biology, and cell cultures.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: March 21, 2027
• Est. primary completion date: November 21, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 75 years.

• Unifocal disease.

• Unilobar tumor.

• Clinical-radiological diagnosis of supratentorial unicentric high-grade glioma, eligible for macroscopically complete resection.

Exclusion Criteria:

• Multilobar tumor, interhemispheric or infratentorial extension, or multifocal disease.

• Midline shift greater than 1 cm.

• Intracranial hypertension symptoms requiring corticosteroid treatment.

• Synchronous neoplasia.

• Any contraindication for surgery, radiotherapy, or TMZ treatment.

• Cognitive impairment.

• Rejection of informed consent.

• Inability to follow up for 2 years.

• Women of childbearing potential according to the Clinical Trial Facilitation Group (CTFG) criteria. (https://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG /2020_09_HMA_CTFG_Contraception_guidance_Version_1.1.pdf)

• Hypersensitivity to the active ingredient or any excipients of the investigational drug.

Related Conditions & MeSH terms

• Cancer Brain
• Glioblastoma
• Glioblastoma Multiforme
• Glioblastoma, IDH-wildtype
• Radiotherapy; Complications

Intervention

Radiation:
• hypofractionated stereotactic radiotherapy
conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period

Procedure:
• Stereotactic biopsy
Stereotactic biopsy
• resection
supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring

Drug:
• Chemotherapy
4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months

Radiation:
• radiotherapy Stupp protocol
radiotherapy + TMZ concurrently after 4 weeks of resection surgery, as per usual protocol: Three-dimensional radiotherapy planning to deliver a total dose of 60 Gy, with a fractionation of 2 Gy/day, 5 days/week, encompassing a 1-2 cm margin around the contrast-enhancing region defined on T1 imaging or the entire abnormal volume defined on T2 or FLAIR imaging (Li et al., 2016) + TMZ at 75 mg/m2/day for 7 days/week, for 6 weeks during radiotherapy.

Drug:
• Chemotherapy Stupp Protocol
temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.

Locations

Country	Name	City	State
Spain	Hospital Clínico San Carlos	Madrid

Sponsors (2)

Lead Sponsor	Collaborator
Hospital San Carlos, Madrid	Asociación de Afectados Por Tumores Cerebrales en España (ASATE)

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Emergent Adverse Events assessed by physical and neurological examination	Information on adverse events will be reviewed through direct questioning of the patient.	Clinical follow-up every month for 2 years
Primary	Emergent Adverse Events assessed by evaluation of the results of the analysis with hematology and biochemistry.	Information on adverse events will be reviewed through the results of examinations, complementary tests and analytical parameters.	Clinical follow-up every month for 2 years
Primary	Emergent Adverse Events assessed by brain RM image	brain RM image, for neuroradiological follow-up	every 3 months after surgery, for 2 years
Primary	Emergent Adverse Events assessed by AC_PET with 18-FdG	AC_PET image, for neuroradiological follow-up	every 6 months after surgery, for 2 years
Secondary	Efficacy assessed by progression-free survival (PFS)	Progression-free survival (PFS), a measure of how long a patient receives treatment before the cancer begins to grow.	through study completion, an average of 2 yeas.
Secondary	Efficacy assessed by overall survival (OS)	Overall survival (OS), how long patients live after starting treatment.	through study completion, an average of 2 yeas.
Secondary	Quality of life assessed by The Functional Assessment of Cancer Therapy-Brain (FACT-Br)	A commonly used instrument measuring general quality of life (QOL) that reflects symptoms or problems associated with brain malignancies across 5 scales. Patients rate all 5 items using a five-point Likert scale ranging from 0 "not at all" to 4 "very much." Overall, higher ratings suggest higher QOL	every 3 months after surgery, for 2 years
Secondary	Cognitive functionality assessed by MONTREAL COGNITIVE ASSESSMENT (MOCA)	It has been shown to be useful at detecting cognitive dysfunction in brain metastases.; The test is a one-page, 30-point test that can be administered in 10 minutes. It assesses short-term memory recall (5 points), visuospatial abilities through clock-drawing (3 points) and cube copy (1 point), and orientation (6 points). Executive function is assessed through modified Trail Making Part B (1 point), phonemic fluency (1 point), and verbal abstraction (2 points). A sustained-attention task (1 point), digit span (2 points), and serial calculation (3 points) test attention, concentration, and working memory. And lastly, language is assessed through naming low-familiarity animals (3 points), sentence repetition (2 points), and the fluency task	every 3 months after surgery, for 2 years